From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
developers must address multiple constraints simul- taneously: limited sample availability, inhibitor-rich matrices, decentralized testing environments, and the need for standardization across clinical sites. Success lies in designing assays with high-performance chemistry, automation compatibility, and logistical resilience built in from the start. Meridian is an unparalleled partner in the develop- ment of workflow-efficient oncology assays, offering technical expertise and a portfolio of high-perfor- mance reagents to support success from concept to References 1. Hanna, T. P., et al. (2020). Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ , 371 , m4087. https://doi.org/10.1136/bmj.m4087 2. American Cancer Society. (n.d.). Treating non-small cell lung cancer by stage . In Cancer.org . Retrieved June 23, 2025, from https://www.cancer.org/cancer/types/lung-cancer/ treating-non-small-cell/by-stage.html 3. Steiert, T. A., et al. (2023). A critical spotlight on the para- digms of FFPE-DNA sequencing. Nucleic Acids Research, 51 (14), 7143-7162. https://doi.org/10.1093/nar/gkad519 4. Wan, J. C. M., et al. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17 (4), 223-238. https://doi. org/10.1038/nrc.2017.7 5. Schrader, C., et al. (2012). PCR inhibitors – Occur- rence, properties and removal. Journal of Applied Microbiology, 113 (5), 1014-1026. https://doi. org/10.1111/j.1365-2672.2012.05384.x
commercialization. This includes inhibitor-tolerant, highly processive, high-concentration enzymes and mixes in lyophilization-ready or air-dryable formats, engineered for robustness in low-input, inhibitor-rich, and complex clinical samples. Backed by decades of enzymology expertise, Meridian helps assay developers create integrated, workflow-optimized solutions that reduce development time, simplify manufacturing, and accelerate clinical deployment— ultimately enabling more timely, equitable and effective cancer care. n 6. Brown, T. (2017, April 27). Prevent assay drift in your clinical NGS assay by avoiding 2 common mistakes . SeraCare Life Sciences: Diagnostic Precision. https://blog. seracare.com/ngs/prevent-assay-drift-in-your-clinical-ngs- assay-by-avoiding-2-common-mistakes 7. Ball, M., et al. (2025). Clinical implementation of a high- throughput automated comprehensive genomic profiling test: TruSight Oncology 500 HT. The Journal of Molecular Diagnostics, 27 (2), 154-162. https://doi.org/10.1016/j.jmoldx.2024.11.005 8. Woodard, W. (2023). How to Eliminate Hidden Cold Chain Costs- Lyophilizing Diagnostic Assays [White paper] . Argonaut Manufacturing Services . https://www.argo- nautms.com/wp-content/uploads/2025/01/AMS-Whitepa- per_-LyophilizingTotalLandedCost.pdf
34 | GENengnews.com
Powered by FlippingBook